Gatifloxacin is the fourth generation of fluoroquinolones, which belongs to 8-methoxyfluoroquinolones racemic compound. It has broad-spectrum anti gram negative and positive microorganisms and activity. It was first developed by Xinglin Pharmaceutical Co., Ltd. of Japan. Its R - and s-enantiomers have the same antibacterial activity. It can inhibit bacterial DNA replication by inhibiting DNA gyrase and topoisomerase IV It plays an important role in the process of transcription and repair. It has strong antibacterial effect on a variety of bacteria, and has good curative effect on respiratory and reproductive system infections. It is one of the representatives of "respiratory fluoroquinolones" which have been growing rapidly in recent years. It is mainly used for the treatment of various mild and moderate infectious diseases caused by sensitive pathogens, including chronic bronchitis, acute sinusitis, community-acquired pneumonia, simple urinary tract infection (cystitis), complicated urinary tract infection, cystitis, acute pyelonephritis and infection of urethra, cervix and rectum caused by Neisseria gonorrhoeae.